What clinical alternatives to whole liver transplantation? current status of artificial devices and hepatocyte transplantation

Transplantation

Volumn 87, Issue 4, 2009, Pages 457-466

  Sgroi, Antonino ^a   Serre Beinier, Veronique ^a   Morel, Philippe ^a   Bühler, Leo ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Artificial liver support; Bioartificial liver support; Fulminant liver failure; Hepatocyte transplantation

Indexed keywords

ALBUMIN; BASILIXIMAB; CHARCOAL; CORTICOSTEROID; PREDNISOLONE; TACROLIMUS;

ACUTE ON CHRONIC LIVER FAILURE; ALBUMIN DIALYSIS; ALCOHOL LIVER DISEASE; ANION EXCHANGE; ARTIFICIAL LIVER; BIOARTIFICIAL LIVER; BIOREACTOR; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CHRONIC DISEASE; CLINICAL TRIAL; CRIGLER NAJJAR SYNDROME; FATTY LIVER; GRAFT REJECTION; HEPATOCYTE TRANSPLANTATION; HEPATORENAL SYNDROME; HOLLOW FIBER REACTOR; HUMAN; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; LIVER GRAFT; LIVER REGENERATION; LIVER SUPPORT; LIVER TRANSPLANTATION; MOLECULAR ABSORBENT RECIRCULATING SYSTEM; MUSHROOM POISONING; ORGAN DONOR; PLASMAPHERESIS; PRIORITY JOURNAL; RADIAL FLOW BIOREACTOR; REFSUM DISEASE; REVIEW; VIRUS HEPATITIS; DONOR; EDITORIAL; EQUIPMENT DESIGN; LIVER CELL; PHYSIOLOGY; STATISTICS; TRANSPLANTATION;

CLINICAL TRIALS AS TOPIC; EQUIPMENT DESIGN; HEPATOCYTES; HUMANS; LIVER TRANSPLANTATION; LIVER, ARTIFICIAL; TISSUE DONORS;

EID: 65649124843     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181963ad3     Document Type: Review

References (91)

1. Berne RM, Levy MN, Koeppen BM. Physiology, 5th ed. St-Louis, Mosby 2004.
2. Lee WM. Acute liver failure. N Engl J Med 1993; 329: 1862.
3. Trey C, Davidson C. The management of fulminant hepatic failure. Prog Liver Dis 1970; 3: 282.
4. Fallon MB, McGuire BM, Abrams GA, et al. Acute and chronic hepatitis. In: Andreoli TE, Loscalzo J, Carpenter CCJ, eds. Cecil essentials of medicine 2001.
5. Jalan R, Sen S, Williams R. Prospects for extracorporeal liver support. Gut 2004; 53: 890.
6. Stockmann HB, IJzermans JN. Prospects for the temporary treatment of acute liver failure. Eur J Gastroenterol Hepatol 2002; 14: 195.
7. McLaughlin BE, Tosone CM, Custer LM, et al. Overview of extracorporeal liver support systems and clinical results. Ann N Y Acad Sci 1999: 310.
8. Patzer JF II. Advances in bioartificial liver assist devices Ann N Y Acad Sci 2001; 944: 320.
9. Gupta S, Vermuru RP, Yemeni PR, et al. Hepatocyte transplantation: An alternative system for evaluating cell survival and immunoisolation. Int J Artif Organs 1993; 16: 155.
10. Stange J, Mitzner S. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patient's blood and a bioartificial liver. Int J Artif Organs 1996; 19: 677.
11. Stange J, Mitzner S, Risler T, et al. Molecular adsorbent recycling system (MARS): Clinical results of a new membrane based blood purification system for bioartificial liver support. Artif Organs 1999; 23: 319.
12. Jalan R, Sen S, Steiner C. The molecular adsorbent recycling system (MARS) and transmembrane transport of albumin-bound toxins. Liver Transpl 2005; 7: 853.
13. Tan HK. Molecular adsorbent recirculating system (MARS). Ann Acad Med Singapore 2004; 33: 329.
14. Tan HK, Lim JS, Tan CK, et al. Mars therapy in critically ill patients with advanced malignancy: A clinical and technical report. Liver Int 2003; 23(suppl 3):52.
15. Sen S, Mookerjee RP, Cheshire LM, et al. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol 2005; 43: 142.
16. Zhou XM, Miao JY, Yang Y, et al. Clinical experience with molecular adsorbent recirculating system (MARS) in patients with drug-induced liver failure. Artif Organs 2004; 28: 483.
17. Koivusalo AM, Vakkuri A, Hockerstedt K, et al. Experience of MARS therapy with and without transplantation in 101 patients with liver insufficiency. Transplant Proc 2005; 37: 3315.
18. Chiu A, Chan LM, Fan ST. Molecular adsorbent recirculating system treatment for patients with liver failure: The Hong Kong experience. Liver Int 2006; 26: 695.
19. Di Campli C, Santoro MC, Gaspari R, et al. Catholic university experience with molecular adsorbent recycling system in patients with severe liver failure. Transplant Proc 2005; 37: 2547.
20. Kellersmann R, Gassel HJ, Buhler C, et al. Application of molecular adsorbent recirculating system in patients with severe liver failure after hepatic resection or transplantation: initial single-center experiences. Liver 2002; 22(suppl 2): 56.
21. Novelli G, Rossi M, Pretagostini M, et al. One hundred sixteen cases of acute liver failure treated with MARS. Transplant Proc 2005; 37: 2557.
22. Covic A, Goldsmith DJ, Gusbeth-Tatomir P, et al. Successful use of molecular adsorbent regenerating system dialysis for the treatment of fulminant hepatic failure in children accidentally poisoned by toxic mushroom ingestion. Liver Int 2003;23(suppl 3):21.
23. Rittler P, Ketscher C, Inthorn D, et al. Use of the molecular adsorbent recycling system in the treatment of postoperative hepatic failure and septic multiple organ dysfunction - Preliminary results. Liver Int 2004; 24: 136.
24. Ding YT, Xu QX, Qiu YD, et al. Molecular adsorbent recycling system in treating patients with acute liver failure: A bridge to liver transplantation. Hepatobiliary Pancreat Dis Int 2004; 3: 508.
25. Lai WK, HaydonG,MutimerD,et al. The effectofmolecular adsorbent recirculating system on pathophysiological parameters in patients with acute liver failure. Intensive Care Med 2005; 31: 1544.
26. Boyle M, Kurtovic J, Bihari D, et al. Equipment review: The molecular adsorbents recirculating system (MARS). Crit Care 2004; 8: 280.
27. Novelli G, Rossi M, Pretagostini R, et al. MARS (molecular adsorbent recirculating system): Experience in 34 cases of acute liver failure. Liver 2002; 22(suppl 2): 43.
28. Wilmer A, Nevens F, Evenepoel P, et al. The molecular adsorbent recirculating system in patients with severe liver failure: Clinical results at the K.U Leuven. Liver 2002; 22(suppl 2): 52.
29. Catalina MV, Barrio J, Anaya F, et al. Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Int 2003; 23(suppl 3): 39.
30. Sen S, Davies NA, Mookerjee RP, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: A randomized controlled study. Liver Transpl 2004; 10:1109.
31. Mullhaupt B, Kullak-Ublick GA, Ambuhl P, et al. First clinical experience with molecular adsorbent recirculating system (MARS) in six patients with severe acuteonchronic liver failure. Liver 2002; 22(suppl 2): 59.
32. Kurtovic J, Boyle M, Bihari D, et al. An Australian experience with the molecular adsorbents recirculating system (MARS). Ther Apher Dial 2006; 10: 2.
33. Campli CD, Gaspari R,Mignani V, et al. Successful MARS treatment in severe cholestatic patients with acute on chronic liver failure. Artif Organs 2003; 27: 565.
34. Sorkine P, Ben Abraham R, Szold O, et al. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med 2001; 29: 1332.
35. Choi JY, Bae SH, Yoon SK, et al. Preconditioning by extracorporeal liver support (MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation - A pilot study. Liver Int 2005; 25: 740.
36. Barshes NR, Gay AN, Williams B, et al. Support for acutely failing liver: A comprehensive review of historic and contemporary strategies. J Am Coll Surg 2005; 201: 458.
37. Onodera K, Sakata H, Yonekawa M, et al. Artificial liver support at present and in the future. J Artif Organs 2006; 9: 17.
38. Di Campli C, Zileri Dal Verme L, Andrisani MC, et al. Advances in extracorporeal detoxification by MARS dialysis in patients with liver failure. Curr Med Chem 2003; 10: 341.
39. Novelli G, Rossi M, Pretagostini R, et al. A 3-year experience with molecular adsorbent recirculating system (MARS): Our results on 63 patients with hepatic failure and color Doppler US evaluation of cerebral perfusion. Liver Int 2003; 23(suppl 3): 10.
40. Ambrosino G, Naso A, Feltracco P, et al. Cytokines and liver failure: modification of TNF-and IL-6 in patients with acute on chronic liver decompensation treated with molecular adsorbent recycling system (MARS). Acta Biomed 2003; 74(suppl 2): 7.
41. Awad SS, Swaniker F, Magee J, et al. Results of a phase I trial evaluating a liver support device utilizing albumin dialysis. Surgery 2001; 130: 354.
42. Mitzner SR, Stangee J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6:277.
43. Heemann U, Treichel U, Loock J, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, controlled study. Hepatology 2002; 36: 949.
44. Steiner C, Mitzner S. Experiences with MARS liver support therapy in liver failure: Analysis of 176 patients of the International MARS registry. Liver 2002; 22(suppl 2): 20.
45. Khuroo MS, Khuroo MS, Ferahat KL. Molecular adsorbent recirculating system for acute and acute on chronic liver failure: A meta-analysis. Liver Transpl 2004; 10: 1099.
46. Rifai K, Ernst T, Kretschmer U, et al. Prometheus - a new extracorporeal system for the treatment of liver failure. J Hepatol 2003; 39: 984.
47. Laleman W, Wilmer A, Evenepoel P, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006; 10: R108.
48. Stadlbauer V, Krisper P, Aigner R, et al. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care 2006; 10: R169.
49. Yarmush ML, Dunn JC, Tompkins RG. Assessment of artificial liver support technology. Cell Transplant 1992; 1: 323.
50. Adham M. Extracorporeal liver support: Waiting for the deciding vote. ASAIO J 2003; 49: 621.
51. Poyck PP, Hoekstra R, Chhatta A, et al. Time-related analysis of metabolic liver functions, cellular morphology, and gene expression of hepatocytes cultured in the bioartificial liver of the Academic Medical Center in Amsterdam (AMC-BAL). Tissue Eng 2007; 13: 1235.
52. Hochleitner B, Hengster P, Bucher H, et al. Significant survival prolongation in pigs with fulminant hepatic failure treated with a novel microgravity-based bioartificial liver. Artif Organs 2006; 30: 906.
53. Allen JW, Bhatia SN. Engineering liver therapies for the future. Tissue Eng 2002; 8: 725.
54. Kelly JH, Koussayer T, He D, et al. Assessment of an extracorporeal liver assist device in anhepatic dogs. Artif Organs 1992; 16: 418.
55. Sussman NL, Gislason GT, Conlin CA, et al. The Hepatix extracorporeal liver assist device: Initial clinical experience. Artif Organs 1994; 18: 390.
56. Ellis AJ, Hughes RD, Wendon JA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996; 24: 1446.
57. Millis JM, Kramer DJ, O'Grady, et al. Results of phase 1 trial of the extracorporeal liver assist device for patients with fulminant hepatic failure. Am J Transplantation 2001; 1(suppl 1): 391.
58. Rozga J, Podesta L, LePage E, et al. A bioartificial liver to treat severe acute liver failure. Ann Surg 1994; 219: 538.
59. Demetriou AA, Brown RS Jr, Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004; 239: 660.
60. van de Kerkhove MP, Hoekstra R, Chamuleau RA, et al. Clinical application of bioartificial liver support systems. Ann Surg 2004; 240: 216.
61. van de Kerkhove MP, Di Florio E, Scuderi V, et al. Phase I clinical trial with the AMC-bioartificial liver. Int J Artif Organs 2002; 25: 950.
62. Sauer IM, Obermayer N, Kardassis D, et al. Development of hybrid liver support system. Ann N Y Acad Sci 2001; 944: 308.
63. Sauer IM, ZeillingerK,Obermayer N,et al. Primary human liver cells as sourceof modular extracorporeal liver support - A preliminary report. Int J Artif Organs 2002; 25: 1001.
64. Sauer IM, Kardassis D, Zeillinger K, et al. Clinical extracorporeal hybrid liver support - Phase I study with primary porcine liver cells. Xenotransplantation 2003; 10: 460.
65. Mazariegos GV, Kramer DJ, Lopez RC, et al. Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients. ASAIO J 2001; 47: 471.
66. Morsiani E, Brogli M, Galavotti D, et al. Long-term expression of highly differentiated functions by isolated porcine hepatocytes perfused in a radial-flow bioreactor. Artif Organs 2001; 25: 740.
67. Morsiani E, Pazzi P, Puviani AC, et al. Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients. Int J Artif Organs 2002; 25: 192.
68. Bilir BM, Guinette D, Karrer F, et al. Hepatocyte transplantation in acute liver failure. Liver Transpl 2000; 6: 32.
69. Galvão FH, de Andrade Júnior DR, de Andrade DR, et al. Hepatocyte transplantation: State of the art. Hepatol Res 2006; 36: 237.
70. Habibullah CM, Syed IH, Qamar A. Human fetal hepatocyte transplantation in patients with fulminant hepatic failure. Transplantation 1994; 58: 951.
71. Khan AA, Habeeb A, Parveen N, et al. Peritoneal transplantation of human fetal hepatocytes for the treatment of acute fatty liver of pregnancy: A case report. Trop Gastroenterol 2004; 25: 141.
72. Schneider A, AttaranM, Meier PN, et al. Hepatocyte transplantation in an acute liver failure due to mushroom poisoning. Transplantation 2006; 82: 1115.
73. Fisher RA, Strom SC. Human hepatocyte transplantation: Worldwide results. Transplantation 2006; 82: 441.
74. Mito M, Kusano M, Kawaura Y. Hepatocyte transplantation in man. Transplant Proc 1992; 63: 559.
75. Fox IJ, Chowdhury JR, Kauffman SS, et al. Treatment of the Crigler-Najjar syndrome type 1 with hepatocyte transplantation. N Engl J Med 1998; 338: 1422.
76. Horslen SP, McCowan TC, Goertzen TC, et al. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics 2003; 111(6 Pt 1): 1262.
77. Sokal EM, Smets F, Bourgois A, et al. Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: Technique, safety, and metabolic follow-up. Transplantation 2003; 76: 735.
78. Dhawan A, Mitry RR, Hughes RD, et al. Hepatocyte transplantation for inherited factor VII deficiency. Transplantation 2004; 78: 1812.
79. Stéphenne X, Najimi M, Smets F, et al. Cryopreserved liver cell transplantation controls ornithine transcarbamylase deficient patient while awaiting liver transplantation. Am J Transplant 2005; 5: 2058.
80. Stadlbauer V, Krisper P, Beuers U, et al. Removal of bile acids by two different extracorporeal liver support systemsinacute-on-chronic liver failure. ASAIO J 2007; 53: 187.
81. Hassanein TI, Tofteng F, Brown RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46: 1853.
82. Dethloff T, Tofteng F, Frederiksen HJ, et al. Effect of Prometheus liver assist system on systemic hemodynamics in patients with cirrhosis: A randomized controlled study. World J Gastroenterol 2008; 14: 2065.
83. Ferenci P, Kramer L. MARS and the failing liver - Any help from the outer space? Hepatology 2008; 48: 687.
84. Bissell DM, Arenson DM, Maher JJ, et al. Support of cultured hepatocytes by a laminin-rich gel. Evidence for a functionally significant sub-endothelial matrix in normal rat liver. J Clin Invest 1987; 79: 801.
85. Page JL, Johnson MC, Olsavsky KM, et al. Gene expression profiling of extracellular matrix as an effector of human hepatocyte phenotype in primary cell culture. Toxicol Sci 2007; 97: 384.
86. Dunn JC, Tompkins RG, Yarmush ML. Long-term in vitro function of adult hepatocytes ina collagen sandwich configuration. Biotechnol Prog 1991; 7: 237.
87. Olsavsky KM, Page JL, Johnson MC, et al. Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues. Toxicol Appl Pharmacol 2007; 222: 42.
88. Thomas RJ, Bennett A, Thomson B, et al. Hepatic stellate cells on poly(DL-lactic acid) surfaces control the formation of 3D hepatocyte co-culture aggregates in vitro. Eur Cell Mater 2006; 11: 16; discussion 26.
89. Auth MK, Woitaschek D, Beste M, et al. Preservation of the synthetic and metabolic capacity of isolated human hepatocytes by coculture with human biliary epithelial cells. Liver Transpl 2005; 11: 410.
90. Ambrosino G, Varotto S, Basso SM, et al. Hepatocyte transplantation in the treatment of acute liver failure: Microencapsulated hepatocytes versus hepatocytes attached to an autologous biomatrix. Cell Transplant 2003; 12: 43.
91. Onodera K, Sakata H, Yonekawa M, et al. Artificial liver support at present and in the future. J Artif Organs 2006;9:17.